ME02433B - Nitrooksiderivati prostaglandina - Google Patents
Nitrooksiderivati prostaglandinaInfo
- Publication number
- ME02433B ME02433B MEP-2016-79A MEP7916A ME02433B ME 02433 B ME02433 B ME 02433B ME P7916 A MEP7916 A ME P7916A ME 02433 B ME02433 B ME 02433B
- Authority
- ME
- Montenegro
- Prior art keywords
- integer
- compound
- ono2
- bivalent radical
- defined above
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 229910004679 ONO2 Inorganic materials 0.000 claims 15
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002828 nitro derivatives Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003259 prostaglandin group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000004384 Alopecia Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000006474 Brain Ischemia Diseases 0.000 abstract 2
- 206010048962 Brain oedema Diseases 0.000 abstract 2
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 206010019196 Head injury Diseases 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 231100000360 alopecia Toxicity 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000006752 brain edema Diseases 0.000 abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 235000014632 disordered eating Nutrition 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000018526 Narcotic-Related disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 201000005040 opiate dependence Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Predmetni pronalazak se odnosi na jedinjenje sa skeletom azola koje ima antagonistielo dejstvo prema arginin-vazopresinskom (AVP) receptoru Vlb, kao i na Predmetni pronalazak se odnosi na jedinjenje sa skeletom azola koje ima antagonistielo dejstvo prema arginin-vazopresinskom (AVP) receptoru Vlb, kao i na farmaceutske preparate koji sadde navedeno jedinjenje kao aktivni sastojak, posebno nasredstva za leenje ili prevenciju bolesti kao gto su poreme6aji raspololenja (uldjueujueidepresiju), anksiozni poremedaj, S'izofrenija, Alchajmerova bolest, Parkinsonova bolest,Hantingtonova horeja, poremeeaj ishrane, hipertenzija, gastrointestinalna bolest, zavisnost odnarkotika, epilepsija, cerebralni infarkt, cerebralna ishemija, cerebralni edem, povreda glave,zapaljenje, bolesti u vezi sa imunim sistemom i alopecija. farmaceutske preparate koji sadde navedeno jedinjenje kao aktivni sastojak, posebno na sredstva za leenje ili prevenciju bolesti kao gto su poreme6aji raspololenja (uldjueujuei depresiju), anksiozni poremedaj, S'izofrenija, Alchajmerova bolest, Parkinsonova bolest, Hantingtonova horeja, poremeeaj ishrane, hipertenzija, gastrointestinalna bolest, zavisnost od narkotika, epilepsija, cerebralni infarkt, cerebralna ishemija, cerebralni edem, povreda glave, zapaljenje, bolesti u vezi sa imunim sistemom i alopecija.
Claims (15)
1. Jedinjenje opšte formule (I) ili farmaceutski prihvatljive soli ili stereoizomeri od njega: R-X-Y-ONO2 (I)gde je R ostatak prostaglandina formule (II) :gdesimbol --- predstavlja prostu vezuL jeX je -O- ili -S-,Y je bivalentni radikal koji ima sledeće značenje:a)- ravan ili razgranat C1-C20 alkilen, koji je opciono supstituisan pomoću jednog ili više supstituenata izabranih iz grupe koju čine: halogeni atomi, hidroksi, -ONO2 ili T, gde je T -OC(O)(C1-C10 alkil)-ONO2 ili -O(C1-C10 alkil)-ONO2;- cikloalkilen sa 5 do 7 ugljenikovih atoma na cikloalkilenskom prstenu, gde je prsten opciono supstituisan sporednim lancima T1, gde je T1 ravan ili razgranat C1-C10 alkil; b)c) gde je n ceo broj od 0 do 20, a n1 je ceo broj od 1 do 20;d)gde jeX1 = -OCO- ili -COO- i R2 je H ili CH3;Z je -(CH)n1- ili je bivalentni radikal definisan gore pod b)n1 je definisan iznad, a n2 je ceo broj od 0 do 2;e)gde:Y1 je -CH2-CH2-(CH2)n2-; ili -CH=CH-(CH2)n2-;Z je -(CH)n1- ili je bivalentni radikal definisan gore pod b)n1, n2, R2 i X1 definisani su iznad;f)gde su:n1 i R2 definisani iznad, R3 je H ili -COCH3; pod uslovom da kada je Y izabran kao bivalentni radikal pomenut pod b)-f), -ONO2 grupa vezana je za -(CH2)n1; g)gde je X2 -O- ili -S-, n3 je ceo broj od 1 do 6 i R2 je definisan iznad;h)gde je:n4 ceo broj od 0 do 10;n5 je ceo broj od 1 do 10;R4, R5, R6, R7 su ili isti ili različiti, ili su H ili ravan ili razgranat niz C1-C4 alkil;gde je -ONO2 grupa vezana zagde je n5 definisan iznad;Y2 je heterociklični zasićeni, nezasićeni ili aromatični 5 ili 6-očlani prsten, koji sadrži jedan ili više heteroatoma izabranih kao azot, kiseonik, sumpor, i izabran je kao
2. Jedinjenje opšte formule (I) prema zahtevu 1 ili njegove farmaceutski prihvatljive soli ili stereoizomeri gde su R, L, X definisani kao i u zahtevu 1, i Y je bivalentni radikal koji je: a) - ravan ili razgranat C1-C20 alkilen, koji je opciono supstituisan pomoću jednog ili više supstituenata izabranih iz grupe koju čine: halogeni atomi, hidroksi, -ONO2 ili T, gde je T - OC(O) (C1-C10 alkil)-ONO2 ili -O(C1-C10 alkil)-ONO2; - cikloalkilen sa 5 do 7 ugljenikovih atoma na cikloalkilenskom prstenu, gde je prsten opciono supstituisan sporednim lancima T1, gde je T1 ravan ili razgranat C1-C10 alkil; b) c) gde je n ceo broj od 0 do 20, a n1 je ceo broj od 1 do 20; d) gde je: n1 definisan iznad, a n2 je ceo broj od 0 do 2; X1 = -OCO- ili -COO- i R2 je H ili CH3; e) gde su: n1, n2, R2 i X1 definisani iznad; Y1 je -CH2-CH2- ili -CH=CH-(CH2)n2-; f) gde su: n1 i R2 definisani iznad, R3 je H ili -COCH3; pod uslovom da kada je Y izabran kao bivalentni radikal pomenut pod b)-f), -ONO2 grupa vezana je za -(CH2)n1; g) gde je X2 -O- ili -S-, n3 je ceo broj od 1 do 6, a R2 je definisan iznad; h) gde je: n4 ceo broj od 0 do 10; n5 ceo broj od 1 do 10; R4, R5, R6, R7 su isti ili različiti, ili su H ili ravan ili razgranat lanac C1-C4 alkil; gde je -ONO2 grupa vezana za gde je n5 definisan iznad; Y2 je heterociklični zasićen, nezasićen ili aromatični 5 ili 6-očlani prsten, koji sadrži jedan ili više heteroatoma izabranih kao azot, kiseonik, sumpor i izabran je od
3. Jedinjenje opšte formule (I) prema bilo kojem od patentnih zahteva od 1 do 2, gde je Y bivalentni radikal koji ima sledeće značenje: a) ravan ili razgranat C2-C6 alkilen, koji je opciono supstituisan sa -ONO2 ili T, gde je T definisan u zahtevu 1; b) gde je n ceo broj od 0 do 5, a n1 je ceo broj od 1 do 5; g) gde je X2 -O- ili -S-, n3 je 1, R2 je definisan u zahtevu 1.
4. Jedinjenje opšte formule (I) prema bilo kom od patentnih zahteva od 1 do 2, gde je Y bivalentni radikal koji ima sledeće značenje: a) ravan ili razgranat C2-C6 alkilen, koji je opciono supstituisan sa -ONO2 ili T, gde je T definisan u zahtevu 1; b) gde je n 0, a n1 je 1; g) gde je X2 -O- ili -S-, n3 je 1, R2 je vodonik;
5. Jedinjenje opšte formule (I) prema bilo kom od patentnih zahteva od 1 do 2, gde je Y bivalentni radikal definiše se kao: d) Y1 -OCO- i-ili- COO- i R2 je H ili CH3; Z je -(CH)n1- ili je bivalentni radikal definisan u patentnom zahtevu 1 pod b) gde je n ceo broj od 0 do 5 n1 je ceo broj od 1 do 5 i n2 je ceo broj od 0 do 2; e) gde je: Y1 -CH2-CH2-(CH2)n2-; ili -CH=CH-(CH2)n2-; Z je -(CH)n1- ili je bivalentni radikal definisan kao pod b) n1, n2, R2 i X1 definisani su kao iznad; f) gde su: n1 i R2 definisani iznad, R3 je H ili COCH3; pod uslovom da je Y izabran kao bivalentni radikal pomenut pod b)-f), -ONO2 grupa vezana je za -(CH2)n1; h) gde je: n4 ceo broj od 0 do 3; n5 je ceo broj od 1 do 3; R4, R5, R6, R7 su isti i oni su svi H; i -ONO2 grupa vezana je za Y2 je 6-očlani zasićeni, nezasićeni ili aromatični heterociklični prsten koji sadrži jedan ili dva atoma azota i izabran je na primer kao
6. Jedinjenje prema zahtevu 1, izabrano iz grupe koju čine:
7. Proces za pripremu jedinjenja opšte formule (I) kao što je definisano u zahtevu 1, koji proces sadrži: i) reagovanje jedinjenja formule (III) gde je L definisan kao u zahtevu 1; P je H ili hidroksilna zaštitna grupa, a W je -OH, Cl, ili -OC(O)R1 gde je R1 ravan ili razgranat C1-C5 alkil; sa jedinjenjem formule (IV) Z-Y-Q, Y je definisan kao u zahtevu 1, Z je HX ili Z1, X je definisan kao u zahtevu 1, a Z1 izabran je iz grupe koju čine: hlor, brom , jod, mezil, tozil; Q je -ONO2 ili Z1 i ii) kada jQ jeste Z1, konvertovanjem dobijeno jedinjenje u koraku i) u nitroderivate pomoću reakcije sa nitratnim izvorom i iii) opciono uklanjanje zaštite jedinjenja dobijenih u koracima i) ili ii).
8. Jedinjenje opšte formule (I) prema zahtevima od 1 do 6 za upotrebu kao medikament.
9. Jedinjenje prema zahtevima od 1 do 6 za upotrebu u tretmanu glaukoma i okularne hipertenzije.
10. Farmaceutske kompozicije koje sadrže farmaceutski prihvatljivi nosač i farmaceutski efektivnu količinu jedinjenja opšte formule (I) i/ili njihove soli ili stereoizomeri kako je definisano u zahtevima od 1-6.
11. Farmaceutske kompozicije prema zahtevu 10 su u pogodnoj formi za topikalnu administraciju.
12. Farmaceutske kompozicije prema zahtevima 10 ili 11 za tretman glaukoma i okularne hipertenzije.
13. Farmaceutske kompozicije prema zahtevima 11 ili 12, pri čemu se jedinjenje opšte formule (I) administrira skao rastvor, suspenzija ili emulzija u oftamološki prihvatljivom nosaču.
14. Farmaceutska kompozicija sadrži smešu jedinjenja formule (I) kao što je definisano u zahtevu 1 i (i) beta blokator, (ii) inhibitor ugljenične anhidraze ili (iii) adrenergični agonist ili njihove nitrooksi derivate.
15. Farmaceutske kompozicije sadrže smešu jedinjenja formule (I) kao što je definisano u zahtevu 1, kao i timolol ili njihove nitrooksi derivate. 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100001 | 2004-01-05 | ||
| EP04804405.1A EP1704141B1 (en) | 2004-01-05 | 2004-12-27 | Prostaglandin nitrooxyderivatives |
| PCT/EP2004/014820 WO2005068421A1 (en) | 2004-01-05 | 2004-12-27 | Prostaglandin nitrooxyderivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02433B true ME02433B (me) | 2016-09-20 |
Family
ID=34778199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-79A ME02433B (me) | 2004-01-05 | 2004-12-27 | Nitrooksiderivati prostaglandina |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US7273946B2 (me) |
| EP (3) | EP1704141B1 (me) |
| JP (1) | JP3984283B2 (me) |
| KR (2) | KR100850133B1 (me) |
| CN (1) | CN100469765C (me) |
| AP (1) | AP2006003638A0 (me) |
| AR (2) | AR047081A1 (me) |
| AU (1) | AU2004313688B2 (me) |
| BR (1) | BRPI0418245B8 (me) |
| CA (1) | CA2551409C (me) |
| CR (2) | CR8498A (me) |
| CY (1) | CY1117417T1 (me) |
| DK (1) | DK1704141T3 (me) |
| EA (1) | EA010595B1 (me) |
| EC (1) | ECSP066684A (me) |
| ES (2) | ES2566800T3 (me) |
| GE (1) | GEP20094780B (me) |
| GT (1) | GT200500293A (me) |
| HR (1) | HRP20160500T1 (me) |
| HU (1) | HUE027357T2 (me) |
| IL (1) | IL176416A (me) |
| MA (1) | MA28284A1 (me) |
| ME (1) | ME02433B (me) |
| MX (1) | MXPA06007678A (me) |
| MY (1) | MY147181A (me) |
| NO (2) | NO337217B1 (me) |
| NZ (1) | NZ548271A (me) |
| OA (1) | OA13356A (me) |
| PA (1) | PA8620901A1 (me) |
| PE (1) | PE20051052A1 (me) |
| PL (1) | PL1704141T3 (me) |
| RS (1) | RS54717B1 (me) |
| SI (1) | SI1704141T1 (me) |
| TN (1) | TNSN06210A1 (me) |
| TW (1) | TWI337994B (me) |
| UA (1) | UA84726C2 (me) |
| UY (1) | UY28709A1 (me) |
| WO (1) | WO2005068421A1 (me) |
| ZA (1) | ZA200605354B (me) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3984283B2 (ja) | 2004-01-05 | 2007-10-03 | ニコックス，ソシエテ アノニム | プロスタグランヂンニトロオキシ誘導体 |
| JP2009501150A (ja) * | 2005-06-29 | 2009-01-15 | ファイザー・インク | プロスタグランジン誘導体 |
| CA2613010A1 (en) * | 2005-06-29 | 2007-01-04 | Pfizer Inc. | Fluoroprostaglandins nitroderivatives |
| CA2647859C (en) * | 2006-03-29 | 2016-01-05 | Nitromed, Inc. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
| US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| WO2008071421A1 (en) * | 2006-12-15 | 2008-06-19 | Nicox S.A. | Nitrate esters of carbonic anhydrase inhibitors |
| CA2671137A1 (en) | 2006-12-15 | 2008-06-26 | Nicox S.A. | Carbonic anhydrase inhibitors derivatives |
| EP2170826B1 (en) | 2007-06-04 | 2022-04-27 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
| WO2009035565A1 (en) * | 2007-09-07 | 2009-03-19 | Qlt Plug Delivery, Inc | Prostaglandin analogues for implant devices and methods |
| US20090111761A1 (en) * | 2007-10-31 | 2009-04-30 | Pamela Lipkin | Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions |
| AR076731A1 (es) * | 2008-05-09 | 2011-07-06 | Pfizer | Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas |
| US7807716B2 (en) * | 2008-09-24 | 2010-10-05 | Oral Delivery Technology Ltd. | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use |
| KR20210123406A (ko) | 2008-12-04 | 2021-10-13 | 충시 위 | 고투과력을 가진 조성물 및 이의 적용 |
| US8637558B2 (en) | 2008-12-30 | 2014-01-28 | Industry-Academic Cooperation Foundation, Chosun University | Thiazolidinedione derivative and use thereof |
| US9162969B2 (en) | 2009-09-15 | 2015-10-20 | Dsm Ip Assets B.V. | Nitrooxyesters, their preparation and use |
| CN101885684B (zh) * | 2010-07-01 | 2013-10-30 | 南京中医药大学 | 带有一氧化氮供体的芳香酸前体药物及其制备方法和其应用 |
| ES2611807T3 (es) | 2011-08-29 | 2017-05-10 | Mati Therapeutics Inc. | Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular |
| HU231203B1 (hu) * | 2011-12-21 | 2021-10-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Új eljárás travoprost előállítására |
| JP6213560B2 (ja) | 2012-05-03 | 2017-10-18 | マティ セラピューティクス，インク． | 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法 |
| ES2841993T3 (es) * | 2012-10-23 | 2021-07-12 | Nicox Sa | Compuestos donantes de óxido nítrico a base de quinona para uso oftálmico |
| JP6306148B2 (ja) * | 2013-04-18 | 2018-04-04 | ニコックス サイエンス アイルランド | 点眼用のキノン系一酸化窒素供与性化合物 |
| CA2935957C (en) | 2014-01-10 | 2023-01-03 | Manistee Partners Llc | Treatment of migraines using topical administration of prostaglandin f2alpha analogs |
| AR102283A1 (es) * | 2014-10-15 | 2017-02-15 | Novartis Ag | Conjugados de prostaglandina y derivados para tratar el glaucoma y la hipertensión ocular |
| US10280138B2 (en) | 2015-03-31 | 2019-05-07 | Nicox S.A. | Nitric oxide donating derivatives of fluprostenol |
| US10047047B2 (en) | 2015-03-31 | 2018-08-14 | Nicox S.A. | Nitric oxide donating derivatives of latanoprost free acid |
| EP3088388A1 (en) | 2015-04-30 | 2016-11-02 | NicOx S.A. | Nitric oxide donating derivatives of prostaglandins |
| HK1256721A1 (zh) | 2015-09-22 | 2019-10-04 | 灰色视觉公司 | 用於治疗眼部病症的化合物和组合物 |
| HU231175B1 (hu) * | 2015-12-04 | 2021-06-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Tetszőleges, előre meghatározott minőségű Latanoprostene bunod előállítása gravitációs kromatográfiával |
| CA3043000A1 (en) * | 2016-11-08 | 2018-05-17 | Bausch & Lomb Incorporated | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
| KR102069205B1 (ko) * | 2017-08-09 | 2020-01-22 | 연성정밀화학(주) | 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체 |
| RU2718744C2 (ru) | 2018-05-17 | 2020-04-14 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Производные простагландина F2альфа для снижения внутриглазного давления |
| CN109988089B (zh) * | 2018-05-29 | 2022-04-26 | 上海凡秦医药科技有限公司 | 一种前列腺素化合物、制备方法及其用途 |
| CN108892624B (zh) * | 2018-06-20 | 2020-12-15 | 重庆威鹏药业有限公司 | 沙库巴曲硝基氧衍生物及其制备方法和应用 |
| US11332433B2 (en) * | 2020-07-24 | 2022-05-17 | Chirogate International Inc. | Process for the preparation of latanoprostene bunod and intermediate thereof and compositions comprising the same |
| CN119350280A (zh) * | 2021-11-18 | 2025-01-24 | 广州楷石医药有限公司 | 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途 |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| CA3195291A1 (en) * | 2022-04-13 | 2023-10-13 | Caravel Therapeutics, Inc. | Preservative-free ophthalmic pharmaceutical emulsion and its application |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3922293A (en) | 1971-12-30 | 1975-11-25 | Upjohn Co | Prostaglandin F-type 9-monoacylates |
| US4952581A (en) | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
| ATE101342T1 (de) | 1988-09-06 | 1994-02-15 | Kabi Pharmacia Ab | Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension. |
| EP0664707B1 (en) | 1992-10-13 | 1997-06-04 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
| US5328933A (en) * | 1992-10-28 | 1994-07-12 | Allergan, Inc. | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues |
| US5625083A (en) | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292377B1 (it) * | 1997-06-19 | 1999-02-08 | Nicox Sa | Composizioni farmaceutiche a base di prostaglandine |
| US6417228B1 (en) | 1998-11-02 | 2002-07-09 | Alcon Manufacturing, Ltd.. | 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| AU3713600A (en) | 1999-03-01 | 2000-09-21 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
| US20030018079A1 (en) | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
| EP1386611A4 (en) * | 2001-04-19 | 2009-05-13 | Teika Pharmaceutical Co Ltd | MEDICAL DEVICES AND MEDICAL SETS |
| JP3984283B2 (ja) * | 2004-01-05 | 2007-10-03 | ニコックス，ソシエテ アノニム | プロスタグランヂンニトロオキシ誘導体 |
-
2004
- 2004-12-27 JP JP2006546105A patent/JP3984283B2/ja not_active Expired - Lifetime
- 2004-12-27 HU HUE04804405A patent/HUE027357T2/en unknown
- 2004-12-27 GE GEAP20049494A patent/GEP20094780B/en unknown
- 2004-12-27 BR BRPI0418245A patent/BRPI0418245B8/pt not_active IP Right Cessation
- 2004-12-27 OA OA1200600221A patent/OA13356A/en unknown
- 2004-12-27 ES ES04804405.1T patent/ES2566800T3/es not_active Expired - Lifetime
- 2004-12-27 EP EP04804405.1A patent/EP1704141B1/en not_active Expired - Lifetime
- 2004-12-27 CA CA2551409A patent/CA2551409C/en not_active Expired - Lifetime
- 2004-12-27 ME MEP-2016-79A patent/ME02433B/me unknown
- 2004-12-27 RS RS20160251A patent/RS54717B1/sr unknown
- 2004-12-27 EP EP19196238.0A patent/EP3643702A1/en not_active Withdrawn
- 2004-12-27 CN CNB2004800398051A patent/CN100469765C/zh not_active Expired - Lifetime
- 2004-12-27 DK DK04804405.1T patent/DK1704141T3/en active
- 2004-12-27 NZ NZ548271A patent/NZ548271A/en not_active IP Right Cessation
- 2004-12-27 AU AU2004313688A patent/AU2004313688B2/en not_active Expired
- 2004-12-27 SI SI200432309T patent/SI1704141T1/sl unknown
- 2004-12-27 MX MXPA06007678A patent/MXPA06007678A/es active IP Right Grant
- 2004-12-27 UA UAA200607454A patent/UA84726C2/ru unknown
- 2004-12-27 EP EP15194684.5A patent/EP3002277B1/en not_active Expired - Lifetime
- 2004-12-27 AP AP2006003638A patent/AP2006003638A0/xx unknown
- 2004-12-27 EA EA200601099A patent/EA010595B1/ru not_active IP Right Cessation
- 2004-12-27 HR HRP20160500TT patent/HRP20160500T1/hr unknown
- 2004-12-27 KR KR1020067013440A patent/KR100850133B1/ko not_active Expired - Lifetime
- 2004-12-27 ES ES15194684T patent/ES2767136T3/es not_active Expired - Lifetime
- 2004-12-27 PL PL04804405T patent/PL1704141T3/pl unknown
- 2004-12-27 KR KR1020087000325A patent/KR100854838B1/ko not_active Expired - Lifetime
- 2004-12-27 WO PCT/EP2004/014820 patent/WO2005068421A1/en not_active Ceased
- 2004-12-31 TW TW093141786A patent/TWI337994B/zh not_active IP Right Cessation
-
2005
- 2005-01-03 AR ARP050100012A patent/AR047081A1/es active IP Right Grant
- 2005-01-03 MY MYPI20050009A patent/MY147181A/en unknown
- 2005-01-04 UY UY28709A patent/UY28709A1/es not_active Application Discontinuation
- 2005-01-04 PE PE2005000037A patent/PE20051052A1/es active IP Right Grant
- 2005-01-04 PA PA20058620901A patent/PA8620901A1/es unknown
- 2005-01-05 US US11/029,698 patent/US7273946B2/en not_active Expired - Lifetime
- 2005-10-18 GT GT200500293A patent/GT200500293A/es unknown
-
2006
- 2006-06-19 IL IL176416A patent/IL176416A/en active IP Right Grant
- 2006-06-28 ZA ZA200605354A patent/ZA200605354B/xx unknown
- 2006-06-29 EC EC2006006684A patent/ECSP066684A/es unknown
- 2006-06-30 CR CR8498A patent/CR8498A/es unknown
- 2006-07-04 TN TNP2006000210A patent/TNSN06210A1/fr unknown
- 2006-07-05 MA MA29169A patent/MA28284A1/fr unknown
- 2006-08-07 NO NO20063567A patent/NO337217B1/no unknown
-
2007
- 2007-08-20 US US11/841,628 patent/US7449469B2/en not_active Expired - Lifetime
-
2008
- 2008-09-15 US US12/210,975 patent/US7629345B2/en not_active Expired - Lifetime
-
2009
- 2009-11-06 US US12/613,985 patent/US7910767B2/en not_active Expired - Lifetime
-
2011
- 2011-02-11 US US13/025,740 patent/US8058467B2/en active Active
- 2011-03-11 CR CR20110131A patent/CR20110131A/es unknown
-
2014
- 2014-12-22 AR ARP140104875A patent/AR098931A2/es not_active Application Discontinuation
-
2015
- 2015-10-08 NO NO20151341A patent/NO339685B1/no unknown
-
2016
- 2016-04-26 CY CY20161100340T patent/CY1117417T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02433B (me) | Nitrooksiderivati prostaglandina | |
| US5618818A (en) | Muscarinic agonist compounds | |
| ES2732758T3 (es) | Derivados de indano e indolina y su uso como activadores de guanilato-ciclasa soluble | |
| AP2001002307A0 (en) | B3 adrenergic receptor agonists and uses thereof. | |
| AU674480B2 (en) | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity | |
| PT97078B (pt) | Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| BR112020008850A2 (pt) | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 | |
| US6563009B1 (en) | Vasodilator cannabinoid analogs | |
| JP2017516806A (ja) | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 | |
| US20020037895A1 (en) | Mevinolin derivatives | |
| IE44739B1 (en) | Adenine derivatives | |
| CA3108046A1 (en) | Benzene derivative | |
| WO2007090733A1 (en) | Nitrooxy derivatives suitable as alpha2 adrenergic receptor agonists | |
| CA2964364A1 (en) | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | |
| CS219943B2 (en) | Method of making the racemic and optically unite derivatives of the 1-phenyl-2-cyclohexene-1-alcylamine | |
| WO2008128832A1 (en) | Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome | |
| CA2613748A1 (en) | Prostaglandin derivatives | |
| CA2613010A1 (en) | Fluoroprostaglandins nitroderivatives | |
| US20200368259A1 (en) | Materials and methods for suppressing and/or treating bone related diseases and symptoms | |
| CN1455770A (zh) | (2－氮杂二环[2.2.1]庚烷－7－基)甲醇衍生物作为烟碱类乙酰胆碱受体激动剂 | |
| CA2671137A1 (en) | Carbonic anhydrase inhibitors derivatives | |
| WO2005002524A3 (en) | COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα | |
| MX2025013088A (es) | Compuesto heterociclico y su uso | |
| WO2025106410A1 (en) | Alpha 4 beta 7 integrin modulators and uses thereof |